- Pfizer Inc.
- Angiosyn Inc.
- Eyetech Inc.
- Aton Pharma Inc.
- Merck & Co. Inc.
- Schering-Plough Corp.
- NeoGenesis Pharmaceuticals Inc.
- Takeda Pharmaceutical Co. Ltd.
- Takeda California Inc.
- Idenix Pharmaceuticals Inc.
- Innoviva Inc.
- Novartis AG
- GlaxoSmithKline PLC
- Genentech Inc.
- Xcel Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- Neuro3d SA
- Boston Scientific Corp.
- Medtronic PLC
- Pfizer buys Angiosyn in deal based largely on milestones
- Pfizer develops Eyetech's Macugen
- Merck & Co. buys Aton Pharma
- Schering-Plough acquires NeoGenesis
- Takeda acquires Syrrx
- Roche, Syrrx develop cancer, diabetes compounds
- Novartis gets majority stake in Idenix for CHF352; deal later restructured
- GSK signs broad collaboration with Theravance
- Roche buys remaining 33% stake in Genentech
- Idenix Pharmaceuticals closes $58mm IPO
- Theravance completes $91.5mm IPO
- NeoGenesis files for IPO; withdrawn
- Neuro3d completes €31.5mm third round
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.